Basilea Pharmaceutica has commenced next pharmacokinetic Phase 1 study with antibiotic BAL30072 in healthy volunteers.
The injectable sulfactam antibiotic has the potential to target clinically relevant gram-negative bacteria resistant to multiple drugs including Pseudomonas or Acinetobacter species.
Basilea chief medical officer Prof. Achim Kaufhold said BAL30072 potent antimicrobial activity makes the drug useful to treat serious and life-threatening infections caused by Gram-negative bacteria for which only limited therapeutic options exist at present.
"Due to its potent antimicrobial activity BAL30072 has the potential to play an essential role in the therapy of serious and life-threatening infections caused by Gram-negative bacteria for which currently only limited therapeutic options exist," Prof. Kaufhold added.
"We are now expanding our phase 1 clinical program for this promising drug candidate to optimize dosing regimens in preparation for phase 2 clinical studies."
BAL30072 cannot be readily destroyed by bacterial enzymes, which cause resistance to many marketed antibiotics, such as extended-spectrum beta-lactamases, carbapenemases or the New Delhi metallo-beta-lactamase 1.
